Researchers from the University of California San Diego and University of Texas Southwestern Medical Center have created a detailed structural map of GABAA receptors in the human brain. Published in Nature, this study provides unprecedented insights into how these crucial proteins assemble and interact with drugs.
GABAA receptors, composed of 19 subunits, play a vital role in controlling neuronal communication and are targets for various medications treating epilepsy, anxiety, depression, and insomnia. However, technical limitations had previously hindered a comprehensive understanding of their structure in human brain tissue.
The research team, led by Ryan Hibbs, overcame these challenges by directly examining human brain samples obtained from epilepsy patients undergoing surgery. Using advanced cryo-electron microscopy, the scientists created 3-D structural models of 12 GABAA receptor subunit assemblies.
This breakthrough revealed the diverse ways subunits combine to form receptors and uncovered new drug mechanisms potentially relevant to epilepsy treatment. The study also employed electrophysiology to measure receptor function and drug responses.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
“This research helps explain how the brain’s ‘brakes’ work—how neurons slow down or stop firing,” said Jia Zhou, the paper’s lead author. “By understanding this process, scientists can create better treatments for conditions like epilepsy, anxiety and insomnia."
The research has already yielded unexpected findings, including novel functions for two epilepsy drugs previously not known to act on GABAA receptors. This new knowledge could explain why certain medications succeed or fail in treating neurological disorders.
Moving forward, the team plans to investigate how different subunit combinations affect receptor functions across brain regions and explore the design of more targeted drugs. They also aim to extend their studies to patients with specific neurological conditions, potentially leading to customized therapies.